维普期刊资源整合服务平台（V6.5）

50篇 您的检索式：作者名="Buckstein"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	High-Dose celecoxib and metronomic 'low-dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma显示文摘	Buckstein R Kerbel R S Shaked Y	2006	Clin Cancer Res2006，12，17：	1
2	查看详情显示文摘	Buckstein M H He J Rubin H		0，，：	1
3	The irnmunomodulato- ry agents lenalidomide and thalidomide for treatment of the my- elodysplastic syndromes: aclinical practice guideline 显示文摘	Leitch HA Buckstein R Shamy A	2013	Crit Rev Oncol Hematol2013，85，2：	1
4	Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA 显示文摘	Kariko K Buckstein M Ni H	2005	Immunity2005，23，2：	1
5	High - dose celecoxib and metronomic ' low - dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non -Hodgkin's lymphoma显示文摘	Buckstein R Kerbel RS Shaked Y	2006	Chn Cancer Res2006，12，17：	1
6	5-Azacytidine in myelodysplastic syndromes:a clinical practice guideline显示文摘	Buckstein R Yee K Wells RA		0，，02：	1
7	Lenalidomide andmetronomic melphalan for CMML and higher risk MDS: a phase 2clinical study with biomarkers of angiogenesis显示文摘	Buckstein R Kerbel R Cheung M	2014	Leuk Res2014，38，7：	1
8	CNS prophylaxis and treatment in non- Hodgkin's lymphoma: variation in practice and lessons from the literature 显示文摘	Buckstein R Lim W Franssen E	2003	Leuk Lymphoma2003，44，6：	1
9	Rituximab purging and maintenance combined with auto-SCT:long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma显示文摘	Hicks LK Woods A Buckstein R	2009	Bone Marrow Transplant2009，43，5：	1
10	5-Azacytidine in myelodysplastiesyn- dromes: a clinical practice guideline 显示文摘	Buckstein R Yee K Wells RA	2011	Cancer TreatRev2011，37，2：	1
11	High-Dose celecoxib and metronomic 'low-dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkins lymphoma显示文摘	Buckstein R Kerbel RS Shaked Y	2006	Clin Cancer Res2006，12，17：	1
12	Safety and efficacy ofthrombopoietin-receptor agonists in myelodysplastic syndromes:asystematic review and meta-ana\ys\s of randomized controlledtrials显示文摘	Prica A Sholzberg M Buckstein R	2014	Br J Hematol2014，167，5：	1
13	Iron overload in myelodysplastic syndromes:a Canadian consensus guideline显示文摘	Wellos RA Leber B Buckstein R	2008	Leuk Res2008，32，9：	1
14	The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes 显示文摘	Stock RG Buckstein M Liu JT	2013	BJU Int2013，112，：	1
15	High-dose celecoxib and metronomic 'low-dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma显示文摘	Buckstein R Kerbel RS Shaked Y	2006	Clin Cancer Res2006，12，17：	1
16	5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline显示文摘	Buckstein R Yee K Wells RA	2011	Cancer Treat Rev2011，37，2：	1
17	Iron overload in myelodysplastic syndromes: a Canadian consensus guideline显示文摘	Wells RA Leber B Buckstein R	2008	Leuk Res2008，32，9：	1
18	Bcl-2 clearance:optimizing outcomes in follicular non-Hodgkin's lymphoma显示文摘	Berinstein NL Buckstein R Imrie K	2002	Bone Marrow Tranplant2002，29，1：	1
19	Bcl-2 clearanee optimising outcomes in follicular non-Hodgkin' s lymphoma 显示文摘	Berinstein NL Buckstein R Imrie K	2002	Bone Marrow Transplant2002，29，1：	1
20	High-Dose celecoxib and metronomic 'low-dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma显示文摘	Buckstein R Kerbel RS Shaked Y	2006	Clin Cancer Res2006，12，17：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示